BR112017012487A2 - composição aquosa - Google Patents

composição aquosa

Info

Publication number
BR112017012487A2
BR112017012487A2 BR112017012487A BR112017012487A BR112017012487A2 BR 112017012487 A2 BR112017012487 A2 BR 112017012487A2 BR 112017012487 A BR112017012487 A BR 112017012487A BR 112017012487 A BR112017012487 A BR 112017012487A BR 112017012487 A2 BR112017012487 A2 BR 112017012487A2
Authority
BR
Brazil
Prior art keywords
aqueous composition
salt
compound
brimonidine
solvate
Prior art date
Application number
BR112017012487A
Other languages
English (en)
Inventor
Sawai Isamu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR112017012487A2 publication Critical patent/BR112017012487A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

é fornecida uma técnica para suprimir a precipitação cristalina de uma composição aquosa contendo um derivado de isoquinolina halogenado, durante preservação em baixa temperatura. composição aquosa, caracterizada pelo fato de que compreende um composto representado pela fórmula (1): em que x representa um átomo de halogênio, ou um sal do mesmo, ou um solvato do composto ou do sal do mesmo, e brimonidina ou um sal do mesmo.
BR112017012487A 2014-12-12 2015-12-11 composição aquosa BR112017012487A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014251708 2014-12-12
PCT/JP2015/084802 WO2016093344A1 (ja) 2014-12-12 2015-12-11 新規水性組成物

Publications (1)

Publication Number Publication Date
BR112017012487A2 true BR112017012487A2 (pt) 2017-12-26

Family

ID=56107521

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012487A BR112017012487A2 (pt) 2014-12-12 2015-12-11 composição aquosa

Country Status (11)

Country Link
US (1) US10220043B2 (pt)
EP (1) EP3231429B1 (pt)
JP (2) JP5951920B1 (pt)
KR (1) KR102502053B1 (pt)
CN (1) CN107106571B (pt)
BR (1) BR112017012487A2 (pt)
CA (1) CA2970263A1 (pt)
MX (1) MX2017007573A (pt)
MY (1) MY178881A (pt)
SG (1) SG11201704737SA (pt)
WO (1) WO2016093344A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3199161T3 (da) * 2014-09-25 2022-01-03 Kowa Co Farmaceutisk præparat
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
KR20200103041A (ko) * 2017-12-21 2020-09-01 산텐 세이야꾸 가부시키가이샤 오미데네팍의 조합
WO2019235456A1 (ja) * 2018-06-05 2019-12-12 千寿製薬株式会社 水性液剤
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
CN109734701B (zh) * 2019-03-04 2020-07-14 中国药科大学 Rock抑制剂-二氯乙酸复盐及其制备方法和用途
CN111518028A (zh) * 2020-05-12 2020-08-11 中国药科大学 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途
CN116159018A (zh) * 2023-03-01 2023-05-26 中国药科大学 一种新型外用溴莫尼定凝胶剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
CA2559630C (en) 2004-03-16 2012-04-17 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
WO2006115244A1 (ja) 2005-04-25 2006-11-02 D. Western Therapeutics Institute, Inc. ４－ブロモイソキノリン誘導体及びこれを含有する医薬
EP1902731B1 (en) * 2005-06-21 2013-04-10 Kowa Company, Ltd. Preventive or remedy for glaucoma
JP4800720B2 (ja) * 2005-09-21 2011-10-26 興和株式会社 点眼用組成物
JP2012250953A (ja) 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とα２受容体作動薬の組合せ剤
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
TWI699205B (zh) 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法

Also Published As

Publication number Publication date
JP2016155870A (ja) 2016-09-01
EP3231429A4 (en) 2018-08-08
US10220043B2 (en) 2019-03-05
EP3231429B1 (en) 2021-03-17
JP5951920B1 (ja) 2016-07-13
SG11201704737SA (en) 2017-07-28
CN107106571B (zh) 2021-02-05
CN107106571A (zh) 2017-08-29
EP3231429A1 (en) 2017-10-18
KR102502053B1 (ko) 2023-02-20
WO2016093344A1 (ja) 2016-06-16
US20170360799A1 (en) 2017-12-21
JPWO2016093344A1 (ja) 2017-04-27
CA2970263A1 (en) 2016-06-16
MY178881A (en) 2020-10-21
MX2017007573A (es) 2018-01-17
KR20170095847A (ko) 2017-08-23

Similar Documents

Publication Publication Date Title
BR112017012487A2 (pt) composição aquosa
BR112017012491A2 (pt) composição
BR112017006148A2 (pt) produto farmacêutico
BR112017012483A2 (pt) composição aquosa
PH12016500169A1 (en) Polymorph of syk inhibitors
BR112017002827A2 (pt) derivado de quinolina altamente puro e método para produção do mesmo
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
BR112017006253A2 (pt) novos compostos
BR112017006149A2 (pt) preparação farmacêutica
BR112015018188A2 (pt) composição e método para o controle de pestes
BR112017003898A2 (pt) análogos de dioxolano de uridina para o tratamento de câncer
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112017004925A2 (pt) composição e método
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112016021428A2 (pt) método para produção de metaloaluminofosfatos com troca de metais pela troca iônica no estado sólido em baixas temperaturas
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
BR112017004166A2 (pt) sal de derivado de cefalosporina, forma sólida cristalina do mesmo e método para produzir o mesmo
MX2017003941A (es) Composicion acuosa.
CY1120402T1 (el) Νεο αλας ιμβαμπραδινης και μεθοδος παρασκευης αυτου
EA201650042A1 (ru) Соль цинка или меди(ii) и ее применение в качестве биоцида
TH170794B (th) เกลือของอนุพันธ์เซฟาโลสปอริน, ของแข็งคริสตัลไลน์ของมัน และวิธีของการผลิตของมัน
TH168624B (th) อนุพันธ์กลูโคไพแรโนซิล-ซับสทิทิวเทด อินโดล-ยูเรีย และการใช้สารเหล่านั้น เป็นตัวยับยั้ง sglt
PL407842A1 (pl) Sole amoniowe o czynności herbicydowej
AR103070A1 (es) Derivados de 5-clorobenzo[d]isoxazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.